Open-angle Glaucoma
📧 Sign up to get email alerts when something new happens for Open-angle Glaucoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-09FDA Approved: COSOPT PF — Supplemental Application (Thea Pharma Inc.)
The FDA approved a supplemental application for COSOPT PF (dorzolamide hydrochloride and timolol maleate) by Thea Pharma Inc., marking an ad…
-
FDA approval · 2026-03-18FDA Approved: APRACLONIDINE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for apraclonidine from Sandoz Inc.
-
FDA approval · 2026-03-18FDA Approved: IOPIDINE 1% — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) from Harrow Eye, LLC, indicating a…
-
FDA approval · 2026-03-17FDA Approved: COMBIGAN — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for COMBIGAN (brimonidine tartrate and timolol maleate) submitted by Allergan, Inc.
-
FDA approval · 2026-03-11FDA Approved: BRIMONIDINE TARTRATE — Original Application (Gland Pharma Limited)
FDA approved the original application for brimonidine tartrate ophthalmic solution from Gland Pharma Limited. The approval adds a generic op…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-06EMA Authorised: Azarga (brinzolamide;timolol maleate) — Novartis Europharm Limited
EMA authorised Azarga, a fixed-dose combination of brinzolamide and timolol, for open-angle glaucoma and ocular hypertension; applicant: Nov…
-
EMA approval · 2026-01-23EMA Authorised: Travatan (travoprost) — Novartis Europharm Limited
EU marketing authorisation granted for Travatan eye drops (travoprost) by Novartis Europharm Limited for glaucoma (open-angle) and ocular hy…
-
EMA approval · 2026-01-15EMA Authorised: Rhokiinsa (netarsudil) — Santen Oy
The EMA authorised Rhokiinsa (netarsudil) by Santen Oy for open-angle glaucoma and ocular hypertension.
-
FDA approval · 2026-01-08FDA Approved: ACETAZOLAMIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for acetazolamide from Strides Pharma Science Limited. The document indicates approval of a suppleme…
-
FDA approval · 2025-12-17FDA Approved: LATANOPROST OPHTHALMIC SOLUTION — Original Application (Lifestar Pharma LLC)
FDA approved an original application for latanoprost ophthalmic solution from Lifestar Pharma LLC, providing a generic version of latanopros…
-
FDA approval · 2025-12-17FDA Approved: TRAVOPROST OPHTHALMIC SOLUTION — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Travoprost Ophthalmic Solution under an Original ANDA filed by Alembic Pharmaceuticals, indicated to reduce intraocular pressur…
-
FDA approval · 2025-10-09FDA Approved: TRAVATAN Z — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRAVATAN Z (travoprost) submitted by Novartis Pharmaceuticals Corporation, resulting in chan…
-
FDA approval · 2025-09-22FDA Approved: BIMATOPROST — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the original application for bimatoprost from Amneal Pharmaceuticals NY LLC, enabling a generic version of the ophthalmic thera…
-
FDA approval · 2025-09-18FDA Approved: ALPHAGAN P — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for ALPHAGAN P (brimonidine tartrate) from Allergan, Inc., regarding labeling changes. The product i…
-
FDA approval · 2025-09-18FDA Approved: ALPHAGAN P — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for Alphagan P (brimonidine tartrate) submitted by Allergan, Inc.
-
FDA approval · 2025-09-09FDA Approved: ZOLYMBUS — Original Application (Thea Pharma Inc.)
FDA approved ZOLYMBUS (bimatoprost) from Thea Pharma Inc. under NDA217307 as an ocular hypotensive agent to lower intraocular pressure in ad…
-
FDA approval · 2025-05-08FDA Approved: DORZOLAMIDE HYDROCHLORIDE — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for dorzolamide hydrochloride from Sagent Pharmaceuticals, authorizing this generic drug for lowerin…
-
FDA approval · 2025-04-29FDA Approved: LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION, 0.024% — Original Application (Gland Pharma Limited)
The FDA approved a generic latanoprostene bunod ophthalmic solution, 0.024%, from Gland Pharma Limited under an Original Application. It is …
-
FDA approval · 2025-04-25FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for a generic dorzolamide hydrochloride and timolol maleate eye drop from Gland Pharma Limited. The …
-
FDA approval · 2025-04-14FDA Approved: LATANOPROST — Original Application (Micro Labs Limited)
FDA approved latanoprost from Micro Labs Limited through an original application; indicated to reduce intraocular pressure in open-angle gla…
-
FDA approval · 2025-02-25FDA Approved: BRIMONIDINE TARTRATE/TIMOLOL MALEATE OPHTHALMIC SOLUTION — Original Application (Leading Pharma, LLC)
FDA approved a generic fixed-dose combination ophthalmic solution of brimonidine tartrate and timolol maleate from Leading Pharma, LLC under…
-
FDA approval · 2025-02-18FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Original Application (Genus Lifesciences)
FDA approved the original application for a generic dorzolamide hydrochloride and timolol maleate combination to treat elevated intraocular …
-
FDA approval · 2025-02-11FDA Approved: DORZOLAMIDE HYDROCHLORIDE — Original Application (Somerset Therapeutics, LLC)
FDA approved a generic dorzolamide hydrochloride product under an Original Application by Somerset Therapeutics, LLC. Dorzolamide hydrochlor…
-
FDA approval · 2024-11-26FDA Approved: LATANOPROST — Original Application (Sagent Pharmaceuticals)
FDA approved the original application for latanoprost from Sagent Pharmaceuticals (a generic).
-
EMA approval · 2024-11-18EMA Authorised: Lumigan (bimatoprost) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Lumigan (bimatoprost) for open-angle glaucoma and ocular hypertension, with AbbVie Deutschland GmbH & Co. KG as the marke…